Results Tomography and ultrasound evidenced of complex cystic mass with multiple trabeculations and calcifications involving the entire abdomen, massive cystic multiseptated, with thick septa and peritoneal nodules, which presented contrast enhancement, diffusely lining the peritoneal cavity, from the subdiaphragmatic surfaces to the pelvis. Tumoral marker (CA 125) presented alteration (3,630 U/ml). Pathological and immunohistochemistry exam showed malignant neoplasm of epithelial origin, Low-Grade Endometrial Stromal Sarcoma (ESS-LG). The patient was submitted in January 2018 to a cytoreductive surgery with preservation of the fertility, performed appendectomy, left salpingo-oophorectomy with resection of multiples peritoneal implants. Patient is currently in clinical follow-up, using megestrol acetate since March 2018, with no pregnancy schedule so far.

Conclusions ESS-LG are rare malignancies, it affects women in perimenopause and young people. The standard treatment is total hysterectomy and bilateral salpingo-oophorectomy, but in young patients consider the possibility of fertility-sparing to desire for gestation. The viability and safety are still limited due to few studies. Patients who chose to maintain fertility, had low recurrence rates and most of them presented a successful pregnancy, naturally, cesarean delivery, without complications.

IGCS19-0059

426 RETROSPECTIVE STUDY OF EARLY STAGE ENDOMETRIAL CANCER IN PORTSMOUTH HOSPITAL NHS TRUST, UK AN AUDIT ON ADHERENCE OF UNITED KINGDOM GUIDELINES AND OVERALL SURVIVAL

M. Lwin, M. Uherek, G. Khoury, F. Gardner, CC. Yeoh*. Queen Alexander Hospital-Portsmouth NHS Trust-UK, Oncology Department, Portsmouth, UK

10.1136/ijgc-2019-IGCS.426

Objectives We audited the management of early stage (Stage 1) endometrial cancer in our institution’s adherence with British Gynaecological Cancer Society (BGCS) guidelines.

The guidelines state 1) Hysterectomy and bilateral salpingo-oophorectomy is recommended for Grade 1–2 disease. Lymphadenectomy is not recommended in low risk cases. 2) Low risk disease does not require adjuvant treatment, 3) For intermediate risk, adjuvant vaginal vault brachytherapy is recommended. 4) For high intermediate risk to consider external